Affimed (NASDAQ:AFMD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD) in a report issued on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Affimed in a report on Tuesday, December 10th. Wells Fargo & Company decreased their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $13.50.

Affimed Price Performance

NASDAQ:AFMD opened at $0.62 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $0.89 and a 200-day moving average of $1.85. Affimed has a 52 week low of $0.52 and a 52 week high of $8.95.

Institutional Trading of Affimed

Hedge funds have recently modified their holdings of the company. FMR LLC grew its position in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the last quarter. Jane Street Group LLC acquired a new position in Affimed in the third quarter worth $44,000. Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares in the last quarter. Intellectus Partners LLC grew its holdings in shares of Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 32,053 shares during the last quarter. Finally, Northern Trust Corp acquired a new stake in shares of Affimed in the fourth quarter valued at $218,000. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.